| abstract |
The invention relates to a halogenated salicylanilide selected from niclosamide and oxyclozanide, or a pharmaceutically acceptable salt or hydrate thereof, for use in topical anti-inflammatory treatment of one or more clinical signs or symptoms of an inflammatory skin condition in a subject, wherein the one or more clinical signs or symptoms are associated with an abnormal inflammatory response, and the topical anti-inflammatory treatment modulates expression in lesional skin of one or more immune effectors selected from proinflammatory mediators and skin barrier molecules. |